Cutaneous adverse events associated with vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma: an observational study of 30 treated patients and presentation of a management algorithm

被引：0
|
作者：
Sinha, R. [1 ]
Edmonds, K. [2 ]
Newton-Bishop, J. A. [3 ]
Gore, M. [2 ]
Larkin, J. [2 ]
Fearfield, L. A. [1 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Univ Leeds, Leeds, W Yorkshire, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2012年 / 167卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [21] Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
    Wang, Wei
    Smith, Jessica Louise
    Carlino, Matteo Salvatore
    Burmeister, Bryan
    Pinkham, Mark Blayne
    Fogarty, Gerald Blaise
    Christie, David Robert Harry
    Estall, Vanessa
    Shackleton, Mark
    Clements, Arthur
    Wolfe, Rory
    Le Thi Phuong Thao
    Paton, Elizabeth Jane
    Steel, Victoria
    Williams, Narelle Catherine
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 30 : 95 - 99
  • [22] Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia
    Kreitman, Robert J.
    Moreau, Philippe
    Ravandi, Farhad
    Hutchings, Martin
    Gazzah, Anas
    Michallet, Anne-Sophie
    Wainberg, Zev A.
    Stein, Alexander
    Dietrich, Sascha
    de Jonge, Maja J. A.
    Willenbacher, Wolfgang
    De Greve, Jacques
    Arons, Evgeny
    Ilankumaran, Palanichamy
    Burgess, Paul
    Gasal, Eduard
    Subbiah, Vivek
    BLOOD, 2023, 141 (09) : 996 - 1006
  • [23] CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma.
    Ribas, Antoni
    Hodi, F. Stephen
    Kurland, John F.
    Shahabi, Vafa
    Francis, Stephen
    Konto, Cyril
    Joe, Andrew K.
    Lainas, Ioannis
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma
    Larkin, James M. G.
    Del Vecchio, Michele
    Ascierto, Paolo Antonio
    Schachter, Jacob
    Garbe, Claus
    Neyns, Bart
    Mandala, Mario
    Lorigan, Paul
    Miller, Wilson H.
    Guminski, Alexander David
    Berking, Carola
    Rutkowski, Piotr
    Queirolo, Paola
    Hauschild, Axel
    Arance, Ana Maria
    Brown, Michael Paul
    Mitchell, Lada
    Veronese, Maria Luisa
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency
    Bay, Sema Buyukkapu
    Kebudi, Rejin
    Zulfikar, Bulent
    MELANOMA RESEARCH, 2019, 29 (01) : 99 - 101
  • [26] Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
    Sophie Beale
    Rumona Dickson
    Adrian Bagust
    Michaela Blundell
    Yenal Dundar
    Angela Boland
    Ernie Marshall
    Ruth Plummer
    Chris Proudlove
    PharmacoEconomics, 2013, 31 : 1121 - 1129
  • [27] Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
    Beale, Sophie
    Dickson, Rumona
    Bagust, Adrian
    Blundell, Michaela
    Dundar, Yenal
    Boland, Angela
    Marshall, Ernie
    Plummer, Ruth
    Proudlove, Chris
    PHARMACOECONOMICS, 2013, 31 (12) : 1121 - 1129
  • [28] BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
    Meevassana, Jiraroch
    Anothaisatapon, Kullawit
    Subbalekha, Surawish
    Kamolratanakul, Supitcha
    Siritientong, Tippawari
    Ruangritchankul, Komkrit
    Pungrasami, Pornthep
    Hamill, Kevin J.
    Angsapatt, Apichai
    Kitkumthorn, Nakarin
    PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2022, 10 (10) : E4605
  • [29] The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation
    Brown, Michael P.
    Long, Georgina V.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 1 - 15
  • [30] CD44 and CD271 expression and chemoresistance in BRAF V600E/K mutation-positive melanoma
    Hyde, Erin
    Reed, Madison J.
    Baer, Robert W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345